Year-over-year earnings per share growth for the last twelve months: fortebiorx.com (FBRX)

Forte Biosciences Inc - graphic logo of issuer FBRX

Forte Biosciences, Inc. (FBRX) is implementing robotic antibody screening to accelerate the development of therapies for rare skin pathologies. The quarterly EPS growth rate reflects capital dynamics, with the value holding at -2.40. The development strategy is based on the diversification of topical drugs to minimize risks. Competent management led by Paul Wagner is persistently protecting assets while ensuring the search for new growth vectors.

Forte Biosciences (FBRX) - Year-over-year net earnings per share trend for the last twelve months from 07/04/2022 to 09/06/2026

Forte Biosciences (FBRX) - metric breakdowns and financial figures

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:fortebiorx.com - FBRX
Manufactured product of fortebiorx.com

Earnings per share dynamics determine the investment stability of the issuer through the monitoring of cash flows. This metric measures the percentage change in net income for the quarter relative to the previous period. Recorded quarterly EPS growth allows for the identification of capital contraction phases and liquidity risks. For Forte Biosciences, Inc. (FBRX), negative values are expected, as the company is investing in the clinical validation of autoimmune disease therapies. The current pipeline confirms the strategic objective of the business.

Analysis of competing companies

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months EMPG|SLGL (sol-gel.com) - Year-over-year net earnings per share growth for the last 12 months|AXIL (AXIL Brands, Inc.) - Year-over-year earnings per share growth for the last twelve months|MDCX (Medicus Pharma Corp) - Quarterly EPS earnings growth|Verrica Pharmaceuticals (VRCA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth